Literature DB >> 27600602

The concordance of serial ANA tests in an Australian tertiary hospital pathology laboratory.

Adrian Y S Lee1, Andrew R Hudspeth2, Stephen Adelstein3.   

Abstract

The antinuclear antibody (ANA) tests are some of the more frequently requested tests for the diagnosis of autoimmunity. Although they are used primarily as diagnostic blood tests, multiple requests on the same patient continue to be encountered in the laboratory. This retrospective analysis of serial ANA testing at one pathology laboratory in Australia is the first study that examines the statistical concordance and possible implications of this on clinical practice. High-titred ANA have quite good repeatability for titre and pattern, and low-titred ANA, which can be non-specific, have poor repeatability. Staining patterns are, in general, almost random in nature on serial tests when compared to the first-obtained ANA pattern for each patient. This study confirms that there is little benefit in serial ANA testing, and only if there is a clear change in the patient's clinical picture would repeat of an initial low-titred ANA be useful. The findings reinforce the need for pathology stewardship to minimise costs, wasted resources and unnecessary referrals.
Copyright © 2016 Royal College of Pathologists of Australasia. All rights reserved.

Entities:  

Keywords:  Antinuclear antibodies; autoantibodies; connective tissue diseases

Mesh:

Substances:

Year:  2016        PMID: 27600602     DOI: 10.1016/j.pathol.2016.06.003

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

1.  Inter-rater reliability assessment for the new-born screening quality assurance.

Authors:  Leonor Guiñón; Anna Soler; Rosa María López; Sonia Pajares; José Manuel González de Aledo; Ana Argudo-Ramírez; José Luis Marín; Judit García-Villoria; Ángeles Sahuquillo; Luisa Alvarez
Journal:  Biochem Med (Zagreb)       Date:  2022-08-05       Impact factor: 2.515

2.  Fibrillarin antibodies in systemic sclerosis.

Authors:  Adrian Lee
Journal:  Arch Rheumatol       Date:  2021-10-18       Impact factor: 1.007

3.  Identification of a unique anti-Ro60 subset with restricted serological and molecular profiles.

Authors:  A Y S Lee; D Beroukas; L Brown; C Lucchesi; A Kaur; L Gyedu; N Hughes; Y H Ng; O Saran; T P Gordon; J J Wang
Journal:  Clin Exp Immunol       Date:  2020-09-17       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.